KCT0003344尚未招募未知
An open-label, randomized, single dose, crossover pivotal bioequivalence study of fluconazole capsule 50 mg in healthy adult subjects
Pfizer Pharmacueticals Korea0 个研究点目标入组 28 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 55(Year)（—）
- 性别
- All
入选标准
- •1. Healthy male or female subjects between 19 and 55 years.
- •2. No clinically relevant abnormailities identified by blood pressure, pulse rate, 12-lead ECG, physical examination, and laboratory tests.
- •3. Femail subjects without evidences of pregnancy.
- •4. Body mass index of 17.5 to 30.5 kg/m2; and a total body weight over 50 kg.
- •5. A personally signed and dated informed consentt document indicating that the subject has been informed of all pertinent aspects of the trial.
- •6. Subjects who are willing and able to comply with scheduled visits, treatemtn plan, laboratory tests, and other trial procedures.
排除标准
- •1. Present illnesses or histories of clinically significant diseases.
- •2. Any gastrointestinal disorders affecting drug absorption.
- •3. A positive urine durg screen.
- •4. Regular alcohol consumption exceeding 21 units/week (14 units/week for females) within 6 months of screening.
- •5. Treatment with an investigational drug within 3 months or 5 half-lives (whichever is longer) prior to the first dose of trial medications.
- •6. Systolic blood pressure >= 140 mmHg or diastolic blood pressure >= 90mmHg.
- •7. QTc interval > 450 msec or QRS interval > 120 msec in 12-lead ECG.
- •8. AST or ALT >= 2 ULN, or total bilirunin >= 2.0 mg/mL.
- •9. Female subjects of childbearing potential or male subjects who are not willing to use appropriate contraception during the study and for at least 28 days which is longer after the final study drug administration. Femail subjects who are possibly pregnant or breastfeeding.
- •10. Use of prescription or nonprescription drugs, dietary supplements within 7 days or 5 half-lives (which is longer) prior to the first dose of trial medications.
- •11. Use of CYP inducers or inhibitors within 1 month of screening. (Herbal supplements must be discontinued before 28 days prior to the first dose of trail meidations.)
- •12. Blood donations over 1 pint (500 mL) within 60 days prior to dosing. (except plasmapheresis)
- •13. History of sensitivity to heparin or heparin-induced thromnocytopenia.
- •14. Any positive result of HBsAg, anti-HCV, anti-HIV, HIV ag, and RPR.
- •15. Subject unwilling or unable to comply with the lifestyle guidelines.
- •16. Employees or their family of trial sites, bioanalytical laboratories, contract research organizations, and sponsors.
- •17. Subjects whose medical or psychologic status considered ineligible by investigators, suicidal intent or suicide attemps.
- •18. Sensitivity to investigational products, ingredients, or azole derivatives.
- •19. Galactose intolerance, Lapp lactose deficiency, or glucose-galactose malansorption.
研究者
相似试验
已完成
不适用
A clinical trial to evaluate and compare the blood levels of two aliskiren modified release formulations with aliskiren market tablet in healthy adult subjectsCTRI/2011/12/002235ovartis Healthcare Private Limited42
已完成
不适用
The aim of this study is to compare and evaluate the pharmacokinetic properties and safety of oral administration of KD4002Endocrine, nutritional and metabolic diseasesKCT0007759Kyung Dong Pharmaceutical32
已完成
不适用
A randomized, open-label, single dose, crossover study to compare the pharmacokinetic characteristics of the co-administration of metformin SR and rosuvastatin and JLP-1310 in healthy male volunteersKCT0002471Jeil Pharmaceutical40
已完成
不适用
The effect of food on the pharmacokinetics of JLP-1310Endocrine, nutritional and metabolic diseaseKCT0002625Jeil Pharmaceutical16
已完成
不适用
A randomized, open-label, single dose, crossover study to investigate the effect of food on the pharmacokinetics of JLP-1310 in healthy male volunteersEndocrine, nutritional and metabolic diseaseKCT0001497Chonbuk National University Hospital16